TY - JOUR
T1 - Effects of Short-Term Potassium Chloride Supplementation in Patients with Chronic Kidney Disease
AU - Gritter, Martin
AU - Wouda, Rosa D.
AU - Yeung, Stanley M. H.
AU - Wieërs, Michiel L. A.
AU - Geurts, Frank
AU - de Ridder, Maria A. J.
AU - Ramakers, Christian R. B.
AU - Vogt, Liffert
AU - de Borst, Martin H.
AU - Rotmans, Joris I.
AU - Hoorn, Ewout J.
AU - Boom, Henk
AU - Gabreëls, Bas A. Th.F.
AU - Groeneveld, Marc
AU - Janssen, Wilbert M. T.
AU - Korte, Mario R.
AU - Laverman, Goos D.
AU - van der Lubbe, Nils
AU - van der Net, Jeroen B.
AU - Soonawala, Darius
AU - Swart, Reinout M.
AU - K+onsortium
AU - Verhoeven, Martine A. M.
N1 - Funding Information: Funding: This study was supported by the Dutch Kidney Foundation (grants CP16.01 and 21OK+013). Publisher Copyright: Copyright © 2022 by ASN.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Background: Observational studies suggest that adequate dietary potassium intake (90-120 mmol/day) may be renoprotective, but the effects of increasing dietary potassium and the risk of hyperkalemia are unknown. Methods: This is a pre-specified analysis of the run-in phase of a clinical trial in which 191 patients (age 68 ± 11 years, 74% males, 86% European ancestry, eGFR 31 ± 9 mL/min/1.73 m2, 83% renin-angiotensin system inhibitors, 38% diabetes) were treated with 40 mmol KCl/day for two weeks. Results: KCl supplementation significantly increased urinary potassium excretion (72 ± 24 to 107 ± 29 mmol/day), plasma potassium (4.3 ± 0.5 to 4.7 ± 0.6 mmol/L), and plasma aldosterone (281 [198-431] to 351 [241-494] ng/L), but had no significant effect on urinary sodium excretion, plasma renin, blood pressure, eGFR, or albuminuria. Furthermore, KCl supplementation increased plasma chloride (104 ± 3 to 105 ± 4 mmol/L), reduced plasma bicarbonate (24.5 ± 3.4 to 23.7 ± 3.5 mmol/L) and urine pH (all P < 0.001), but did not change urinary ammonium excretion. Twenty-one participants (11%) developed hyperkalemia (plasma potassium 5.9 ± 0.4 mmol/L). They were older and had higher baseline plasma potassium. Conclusions: In patients with CKD stage G3b-4, increasing dietary potassium intake to recommended levels with potassium chloride supplementation raises plasma potassium by 0.4 mmol/L. This may result in hyperkalemia in older patients or those with higher baseline plasma potassium. Longer-term studies should address whether cardiorenal protection outweighs the risk of hyperkalemia.
AB - Background: Observational studies suggest that adequate dietary potassium intake (90-120 mmol/day) may be renoprotective, but the effects of increasing dietary potassium and the risk of hyperkalemia are unknown. Methods: This is a pre-specified analysis of the run-in phase of a clinical trial in which 191 patients (age 68 ± 11 years, 74% males, 86% European ancestry, eGFR 31 ± 9 mL/min/1.73 m2, 83% renin-angiotensin system inhibitors, 38% diabetes) were treated with 40 mmol KCl/day for two weeks. Results: KCl supplementation significantly increased urinary potassium excretion (72 ± 24 to 107 ± 29 mmol/day), plasma potassium (4.3 ± 0.5 to 4.7 ± 0.6 mmol/L), and plasma aldosterone (281 [198-431] to 351 [241-494] ng/L), but had no significant effect on urinary sodium excretion, plasma renin, blood pressure, eGFR, or albuminuria. Furthermore, KCl supplementation increased plasma chloride (104 ± 3 to 105 ± 4 mmol/L), reduced plasma bicarbonate (24.5 ± 3.4 to 23.7 ± 3.5 mmol/L) and urine pH (all P < 0.001), but did not change urinary ammonium excretion. Twenty-one participants (11%) developed hyperkalemia (plasma potassium 5.9 ± 0.4 mmol/L). They were older and had higher baseline plasma potassium. Conclusions: In patients with CKD stage G3b-4, increasing dietary potassium intake to recommended levels with potassium chloride supplementation raises plasma potassium by 0.4 mmol/L. This may result in hyperkalemia in older patients or those with higher baseline plasma potassium. Longer-term studies should address whether cardiorenal protection outweighs the risk of hyperkalemia.
KW - Acidosis
KW - Aldosterone
KW - Chronic kidney disease
KW - Clinical trial
KW - Dietary supplements
KW - Electrolytes
KW - Hypertension
KW - Potassium chloride
UR - http://www.scopus.com/inward/record.url?scp=85131331023&partnerID=8YFLogxK
U2 - https://doi.org/10.1681/ASN.2022020147
DO - https://doi.org/10.1681/ASN.2022020147
M3 - Article
C2 - 35609996
SN - 1046-6673
VL - 33
SP - 1779
EP - 1789
JO - Clinical journal of the American Society of Nephrology
JF - Clinical journal of the American Society of Nephrology
IS - 9
ER -